Neogenomics, Inc.
NEO
$7.42
$0.294.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.17% | 13.42% | 5.06% | 31.11% | -88.89% |
| Total Depreciation and Amortization | -2.53% | 1.13% | -0.67% | -0.88% | -0.51% |
| Total Amortization of Deferred Charges | 0.41% | 0.27% | 0.41% | 0.28% | 0.42% |
| Total Other Non-Cash Items | 20.45% | -4.37% | -7.67% | 13.39% | 9.33% |
| Change in Net Operating Assets | -643.05% | -61.89% | -221.86% | 107.34% | -872.23% |
| Cash from Operations | -358.44% | 5.99% | -33.44% | 153.61% | -245.72% |
| Capital Expenditure | 61.20% | -7.41% | 17.43% | -134.16% | 20.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 31.44% | -15.80% | -64.28% | 1.40% | -17.08% |
| Cash from Investing | 165.12% | -55.49% | -148.08% | -49.65% | -15.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -73.21% | 201.02% | -40.13% | 140.93% | -75.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 38.14% | -41.63% | -40.13% | 140.93% | -35.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -514.70% | -27.32% | -70.19% | 319.13% | -129.17% |